Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
04 nov. 2021 16h05 HE
|
Vir Biotechnology, Inc.
– To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide – – In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration...
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
21 oct. 2021 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter...
Antimicrobial Susceptibility Testing Market Predicted to Reach $4.73 Billion by 2030, Exclusive Report by Allied Market Research
12 oct. 2021 03h18 HE
|
Allied Market Research
Portland, OR, Oct. 12, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global antimicrobial susceptibility testing market generated $3.04 billion in 2020,...
Texas Heart Institute, University of Texas Medical Branch (UTMB) and 7 Hills Pharma Pioneer Significant Vaccine Research
01 oct. 2021 14h59 HE
|
7 Hills Pharma
HOUSTON, TX., Oct. 01, 2021 (GLOBE NEWSWIRE) -- The Texas Heart Institute has announced that a research team led by its Vice President for Research Dr. Darren Woodside and Dr. Peter Vanderslice, of...
Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference
30 sept. 2021 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the Guggenheim...
In-Vitro Diagnostics (IVD) Market Worth $118.5 Billion by 2027 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®
23 sept. 2021 10h23 HE
|
Meticulous Market Research Pvt. Ltd.
London, Sept. 23, 2021 (GLOBE NEWSWIRE) -- According to a new market research report “In Vitro Diagnostics Market by Product & Solution (Consumables, System, Software & Services), Technology...
Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update
13 sept. 2021 16h05 HE
|
Icosavax, Inc.
- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinical trial for IVX-121, a VLP...
Icosavax Appoints Elizabeth Bekiroğlu to General Counsel
10 sept. 2021 08h00 HE
|
Icosavax, Inc.
SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus
09 sept. 2021 08h00 HE
|
Icosavax, Inc.
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Mourns Sudden Passing of Tadataka Yamada, M.D. Chairman of the Company’s Board of Directors
05 août 2021 08h00 HE
|
Icosavax, Inc.
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...